These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32060789)

  • 1. The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome Coronavirus.
    Jiang S; Shi ZL
    Virol Sin; 2020 Jun; 35(3):263-265. PubMed ID: 32060789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mRNA Vaccines: Possible Tools to Combat SARS-CoV-2.
    Yi C; Yi Y; Li J
    Virol Sin; 2020 Jun; 35(3):259-262. PubMed ID: 32524253
    [No Abstract]   [Full Text] [Related]  

  • 3. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.
    Qi X; Ke B; Feng Q; Yang D; Lian Q; Li Z; Lu L; Ke C; Liu Z; Liao G
    Chem Commun (Camb); 2020 Aug; 56(61):8683-8686. PubMed ID: 32613971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
    Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK
    Front Immunol; 2020; 11():1880. PubMed ID: 32973779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Zhang C; Zhou C; Shi L; Liu G
    Hum Vaccin Immunother; 2020 Oct; 16(10):2366-2369. PubMed ID: 32961082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
    Papageorgiou AC; Mohsin I
    Cells; 2020 Oct; 9(11):. PubMed ID: 33105869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2.
    Tai W; Zhang X; Drelich A; Shi J; Hsu JC; Luchsinger L; Hillyer CD; Tseng CK; Jiang S; Du L
    Cell Res; 2020 Oct; 30(10):932-935. PubMed ID: 32759966
    [No Abstract]   [Full Text] [Related]  

  • 10. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.
    Salvatori G; Luberto L; Maffei M; Aurisicchio L; Roscilli G; Palombo F; Marra E
    J Transl Med; 2020 Jun; 18(1):222. PubMed ID: 32493510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
    Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L
    Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronavirus vaccines get a biotech boost.
    Dance A
    Nature; 2020 Jul; 583(7817):647-649. PubMed ID: 32694847
    [No Abstract]   [Full Text] [Related]  

  • 14. Designing Multi-Epitope Vaccines to Combat Emerging Coronavirus Disease 2019 (COVID-19) by Employing Immuno-Informatics Approach.
    Naz A; Shahid F; Butt TT; Awan FM; Ali A; Malik A
    Front Immunol; 2020; 11():1663. PubMed ID: 32754160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2 between humans and mammals.
    Hayashi T; Abiko K; Mandai M; Yaegashi N; Konishi I
    Vet Q; 2020 Dec; 40(1):243-249. PubMed ID: 32921279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain.
    Barh D; Tiwari S; Silva Andrade B; Giovanetti M; Almeida Costa E; Kumavath R; Ghosh P; Góes-Neto A; Carlos Junior Alcantara L; Azevedo V
    F1000Res; 2020; 9():576. PubMed ID: 32802318
    [No Abstract]   [Full Text] [Related]  

  • 17. Potential pathogenesis of severe acute respiratory syndrome coronavirus 2.
    Wu T; Zhang H; Hu E; Ma J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 May; 45(5):591-597. PubMed ID: 32879112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.
    Baig MS; Alagumuthu M; Rajpoot S; Saqib U
    Drugs R D; 2020 Sep; 20(3):161-169. PubMed ID: 32592145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2.
    Mittal A; Manjunath K; Ranjan RK; Kaushik S; Kumar S; Verma V
    PLoS Pathog; 2020 Aug; 16(8):e1008762. PubMed ID: 32822426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development.
    Calina D; Sarkar C; Arsene AL; Salehi B; Docea AO; Mondal M; Islam MT; Zali A; Sharifi-Rad J
    Immunol Res; 2020 Dec; 68(6):315-324. PubMed ID: 33006053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.